Lanreotide Autogel and Octreotide LAR Treatment Patterns: Results from a Nationwide French Retrospective Study

#2969

Introduction: Lanreotide autogel (LAN) and octreotide LAR (OCT) are long acting somatostatin analogues (LA-SSAs) used to treat acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Previous studies conducted in North America and Sweden showed some differences between both LA-SSAs in terms of dose and persistence.

Aim(s): To describe LAN and OCT treatment patterns in France during the year 2017 (most recent available data), using a nationwide claims database (Système National des Données de Santé).

Materials and methods: Patients (pts) who had at least 6 purchases of LAN or OCT during the calendar year 2017 were selected, excluding pts who received both LA-SSAs. Comparisons were made using Student t-test.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Fagnani F, Feuilly M, Marteau F, de Zélicourt M, Kamenicky P,

Keywords: somatostatin analogues, treatment patterns, resource use,